International Journal of Hematology-Oncology and Stem Cell Research 2016. 10(1):30-36.

A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer
Ghasem Janbabai, Ramin Shekarriz, Homa Hassanzadeh, Mohsen Aarabi, Seyyedeh Samaneh Borhani

Abstract


Background: In recent years, epidemiologic and laboratory studies have implied that vitamin D deficiency has a role in the pathogenesis of breast cancer. It has shown that vitamin D can prevent tumor progression induced by carcinogens and inhibit the carcinogenic effects of high fat diet on breast tissue and growth of tumor cells. This study aimed to evaluate serum 25-hydroxyvitamin D level and its role in relation to tumor characteristics and different stages of disease in women with breast cancer.
Subject and Methods: This is a cross-sectional study on 200 patients with breast cancer at different stages of the disease. Information on age, menstrual status, BMI, and tumor characteristics were recorded. Serum 25-hydroxy vitamin D concentrations were measured by refigures dioimmunoassay (RIA). Mean and standard deviation were used to describe the data. Meanwhile, T-test and sum of squares test were used to analyze the data. P<0.05 was considered significant.
Results: Among 200 patients, 47 (23.5%) had severe vitamin D deficiency, 75 (37.5 %) had mild vitamin D deficiency and 78 (39.0 %) had sufficient vitamin D levels of serum. There was a significant correlation between low vitamin D levels and advanced stage of breast cancer, particularly in postmenopausal patients.
Conclusion: It seems that lower levels of vitamin D accompany worse clinicopathologic features. Thus, treatment of vitamin D deficiency in postmenopausal patients might be of great benefits.


Keywords


breast cancer; vitamin D; tumor stage; menopausal status

Full Text:

PDF

References


Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. Apr 2003; 22(2):142-6.

Frappart L, Falette N, Lefebvre MF, et al. In vitro study of effects of 1, 25dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT20. Differentiation. 1989; 40:63–9.

James SY, Mackay AG, Colston KW. Effects of 1, 25 dihydroxy vitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996; 58:395–401.

Jacobson E, James K, Newmark H, et al. Effects of dietary fat, calcium and vitamin D on growth and mammary tumorigenesis induced by 7, 12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989; 49:6300–3.

Colston KW, Chander SK, Mackay AG, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992; 44:693–702.

Anzano MA, Smith JM, Uskokoviv MR, et al. 1a-Dihydroxy-16-ene-23-yne-26,27 hexafluorocholecalci ferol (Ro24–5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 1994; 54:1653–6.

Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989; 320: 980 – 91.

Webb AR, Pilbeam C, Hanafin N, et al. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations or 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990; 51:1075 – 81.

Salamone LM, Dallal GE, Zantos D, et al. contributions of vitamin D intake and seasonal sunlight exposure to plasma 25-hydroxyvitamin D concentration in elderly women. Am J Clin Nutr. 1994; 59: 80 – 6.

Altundag MK, lcli F, Aksoy S, et al. Correlation of levels of seum 25-hydroxivitamin D and lymph node positivity in oprabble breast cancer: a Turkish oncology group. J Clin Oncol. 28:15s, 2010 (suppl; abstr 627).

Alagol F, Shihadeh Y, Boztepe H . Sunlight exposure and vitamin D in Turkish women. J Endocrinol Invest. 2000; 23: 173-7.

Niafar M, Bahrami A, Aliasgharzadeh A. Vitamin D status in healthy postmenopausal Iranian women. J Res Med Sci. 2009 May-Jun; 14(3): 171–177.

Dawodu A, Agarwal M, Hossain M .Hypervitaminosis D and vitamin D deficiency in exclusively brest feeding infants and their mother in summer :a justification for vitamin D supplementation of brest-feeding infants. J Pediatr. 2003; 142:169-73.

Hashemipour S, Larijani B, Adibi H, et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health. 2004; 4: 38.

Palmieri C, Mac Gregor T, Girgis S, et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 2006; 59:1334–1336.

Asvadi Kermani I, Taghavi Kojidi H, Vaez Gharamaleki J, et al. Association of Serum Level of 25 Hydroxy-Vitamin D with Prognostic Factors for Breast Cancer. Asian Pacific J Cancer Prev. 2011; 12: 1381-1384.

Larsson SC, Bergkvist L, Wolk A . Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women. Am J Clin Nutr. 2009; 89: 277-82.

Hatse S, Lambrechts D, Verstuy A, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012; .33 (7):1319–1326.

Kim HJ, Lee YM, Ko BS, et al. Vitamin D deficiency is correlated with poor outcomes in patients with luminal type breast cancer. Ann Surg Oncol. 2011; 18:1830-6.

Peppone LJ, Rickles AS, Janelsins MC, et al. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012; 19(8):2590-9.

Imtiaz S, Siddiqui N, Raza SA, et al. Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J Endocr Metab. 2012;16:409-13.

Garland CF, Garland FC, Gorham ED, et al. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990; 19:614–22.

Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007; 167: 1050–9.

Rossi M, Mc Laughlin JK, Lagiou P, et al. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 2009; 20: 374-8.

Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxy vitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2009; 124: 250–255.

Van Weelden K, Flanagan L, Binderup L, et al. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog EB1089. Endocrinology. 1998; 139:2102–10.

Chouvet C, Vicard E, Devonee M, et al. 1, 25-Dihydroxyvitamin D3 inhibitory effect on growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem. 1986;24: 373–6.

Frappart L, Falette N, Lefebvre MF, et al. In vitro study of effects of 1,25dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT20. Differentiation. 1989; 40:63–9.

James SY, Mackay AG, Colston KW. Effects of 1, 25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996; 58:395–401.

Jacobson E, James K, Newmark H, et al. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7, 12- dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989; 49:6300–3.

Janowsky EC, Lester GE, Weinberg CR, et al. Association between low levels of 1, 25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999; 2: 283–91.

Mawer EB, Walls J, Howell A, et al. Serum 1, 25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1997; 82:118–22.

Albertson DG, Ylstra B, Seagraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000; 25:144–6.

Townsend K, Banwell CM, Guy M, et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 2005; 11:3579–86.

Swami S, Raghavachari N, Muller UR, et al. Vitamin D growth inhibition of breast cancer cells gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003; 80:49–62.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.